Candel Therapeutics Azioni (NASDAQ: CADL)

Ultime notizie per Candel Therapeutics (NASDAQ:CADL) Azioni

Candel Therapeutics

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics Inc

Cadeler AS

Former President Donald Trump has reiterated his commitment to imposing tariffs on cars imported from China and Mexico, aiming to protect American automotive jobs.
What Happened: During an interview with Patrick Bet-David released on Thursday, Trump emphasized the critical role these tariffs would play in safeguarding the U.S. auto industry.
&#8220;I hope the union workers, auto workers understand that I saved their jobs,&#8221; he said.
Trump highlighted a massive car manufacturing plant in Mexico, which he described as potentially one of the largest in the world. He expressed concerns that vehicles from this plant could inundate the U.S. market, leaving little room for American-made cars.
&#8220;That would mean that our car industry is wiped out,&#8221; Trump said.
See Also: <a href="https://www.benzinga.com/news/24/10/41328039/as-elon-musk-unveils-cybercab-uber-ceo-weighs-in-on-robotaxi-competiton-from-waymo-tesla-dont-think?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As Elon Musk Unveils Cybercab, Uber CEO Weighs In On Robotaxi Competiton From Waymo, Tesla: &#8216;Don&#8217;t Think This Is Going To Be A Winner-Take-All Marketplace&#8217;</a>
Why It Matters: In September, Trump <a href="https://www.benzinga.com/news/24/09/40913456/trump-vows-200-tariffs-on-chinese-made-cars-in-mexico-warns-of-us-auto-industry-collapse-if-kamala-h">proposed a 200% tariff</a> on vehicles produced by alleged Chinese factories in Mexico, as reported in a town hall event in Flint, Michigan. He warned that if Vice President Kamala Harris were elected, the U.S. auto industry could collapse within two to three years due to electric vehicle production shifting to China.
Additionally, during a <a href="https://www.benzinga.com/general/politics/24/10/41279272/donald-trump-pushes-tariffs-on-chinese-cars-in-detroit-visit-vows-to-revamp-industry">visit to the Detroit Economic Club</a> in October, Trump reiterated his commitment to tariffs on Chinese cars, vowing to revamp the industry. He also commented on economic indicators, although some of his statements on inflation and interest rates were inaccurate.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41369986/lucid-stock-is-tumbling-wednesday-whats-driving-the-action?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lucid Stock Is Tumbling Wednesday: What&#8217;s Driving The Action?</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Wikimedia Commons

News

General

Trump Defends His Plans To Impose 200% Tariffs On Cars Imported From China, Mexico: 'Hope Union Workers Understand That I Saved Their Jobs'

Amid ongoing global economic recovery efforts, Kristalina Georgieva, Managing Director of the International Monetary Fund, has issued a cautionary note regarding persistent challenges such as high debt and low growth. Her remarks come as the U.S. and EU implement rate cuts to tackle inflation.
What Happened: Georgieva highlighted that despite progress, governments are increasingly reliant on borrowing, which, coupled with &#8220;anemic growth,&#8221; complicates debt management. She praised central banks for their inflation control efforts but noted uneven benefits across regions, with some still facing high prices and related unrest, CNBC <a href="https://www.cnbc.com/2024/10/17/imf-chief-warns-low-growth-and-high-debt-weigh-on-global-economy.html">reported</a> on Friday.
"It's not yet time to celebrate," she said.
"When we look into the challenges ahead of us, the biggest one is low growth, high debt. This is where we can and must do better.&#8221;
Georgieva&#8217;s comments precede the 2024 annual meetings of the IMF and World Bank Group in Washington, D.C., where global economic issues will be discussed. She also pointed out that international trade is no longer the &#8220;engine of growth&#8221; it once was, citing restrictive policies and <a href="https://www.benzinga.com/news/24/09/40914629/china-warns-eu-tariffs-on-evs-will-harm-trade-with-germany">U.S.-EU tariffs against China</a> as potential risks. Additionally, she expressed concern over geopolitical tensions, particularly in the Middle East, affecting global financial stability.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41331839/financial-sector-hits-record-highs-as-goldman-sachs-bank-of-america-citi-beat-q3-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Financial Sector Hits Record Highs As Goldman Sachs, Bank of America, Citi Beat Q3 Earnings Expectations</a>
Why It Matters: Georgieva&#8217;s comment arrived a day after the European Central Bank (ECB) <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41382372/ecb-slashes-rates-again-will-jerome-powell-take-this-as-cue-for-another-fed-rate-"> cut interest rates</a> for the third time this year to stimulate a sluggish economy, shifting focus from inflation control to economic growth. This move follows the Federal Reserve&#8217;s 50 basis point rate cut in September, marking a significant policy shift as both regions tackle economic challenges.
Meanwhile, the U.S. faces a staggering debt situation, with estimates suggesting a<a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40368118/true-us-debt-is-175-trillion-former-coinbase-cto-on-unpayable-crisis"> true national debt </a>of $175 trillion when accounting for entitlements like Social Security and Medicare. This escalating debt underscores the urgency of addressing fiscal challenges.
In China, the government is reportedly considering issuing $850 billion in<a href="https://www.benzinga.com/markets/asia/24/10/41324527/as-chinas-stimulus-hype-wanes-beijing-reportedly-weighs-850b-special-treasury-bonds-to-stimulate-eco"> special treasury bonds</a> to stimulate its slowing economy and manage local debt. These developments highlight the global nature of economic challenges and the varied approaches being taken to address them.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41372368/mark-cuban-battles-former-trump-advisor-for-suggesting-a-child-could-do-american-auto-workers-job-pa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Battles Former Trump Advisor Over Ex-President&#8217;s Comments On American Auto Workers: &#8216;He Still &nbsp;Thinks It&#8217;s 1965&#8217; (UPDATED)</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Macro Economic Events

Global

Economics

As US Tackles Inflation With Rate Cuts, IMF MD Sounds Alarm: 'Not Yet Time To Celebrate' Amid Looming Low Growth, High Debt

The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) will release earnings results for its first quarter, before the <a href="https://www.benzinga.com/quote/PG/earnings">opening bell on Friday, Oct. 18.</a>
Analysts expect the Cincinnati, Ohio-based bank to report quarterly earnings at $1.90 per share, up from $1.83 per share in the year-ago period. Procter &amp; Gamble projects to report revenue of $21.91 billion for the recent quarter, compared to $19.78 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 30, Procter &amp; Gamble reported fourth-quarter FY24 sales of $20.53 billion (flat Y/Y), missing the analyst consensus estimate of $20.74 billion.
Procter &amp; Gamble shares fell 0.1% to close at $172.28 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5890a92043eaaa0001d69b01/linda-bolton%20weiser">DA Davidson analyst Linda Bolton Weiser</a> maintained a Neutral rating with a price target of $159 on Oct. 15. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Lauren Lieberman downgraded the stock from Overweight to Equal-Weight with a price target of $163 on Sept. 30. This analyst has an accuracy rate of 63%.</li>
<li>JP Morgan analyst Andrea Teixeira maintained an Overweight rating and increased the price target from $179 to $186 on Sept. 19. This analyst has an accuracy rate of 61%.</li>
<li>TD Cowen analyst Robert Moskow initiated coverage on the stock with a Buy rating and a price target of $189 on July 23. This analyst has an accuracy rate of 65%.</li>
<li>Stifel analyst Mark Astrachan maintained a Hold rating and raised the price target from $157 to $161 on July 22. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying PG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="482" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png" alt="" class="wp-image-602127" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-1024x482.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158-768x362.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18040800/image-158.png 1365w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

Earnings

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Procter & Gamble Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans,Benson &amp; Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantially similar proposed plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM).
Under the Proposed Plan, if ultimately approved and implemented, RBH, ITL and JTIM (the Companies) would pay an aggregate settlement amount of CAD 32.5 billion (approximately USD 23.5 billion). This amount would be funded by an upfront payment equal to the Companies' cash and cash equivalents on hand in Canada plus certain court deposits (subject to an aggregate withholding of CAD 750 million (approximately USD 540 million) for working capital inclusive of cash pledged as collateral) and annual payments based on a percentage of the Companies' net income after taxes (excluding that generated by certain non-combustible products including heat-not-burn, e-vapor and nicotine pouch products) until the aggregate settlement amount is paid. As stated in the Proposed Plan, the issue of allocation of the CAD 32.5 billion aggregate settlement as between the Companies in the CCAA proceedings remains unresolved.
"After years of mediation, we welcome this important step towards the resolution of long-pending tobacco product-related litigation in Canada," said Jacek Olczak, Chief Executive Officer of PMI. "Although important issues with the plan remain to be resolved, we are hopeful that this legal process will soon conclude, allowing RBH and its stakeholders to focus on the future."

Legal

Philip Morris, Imperial Tobacco, JTI-Macdonald Face $23.5B Settlement in Canada Tobacco Lawsuits

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=3e1a02702fd6e8744473a752dd19c5f5">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced the opening of a new headquarters and technical hub in Lisbon, Portugal to further support its growing EMEA operations and offices in London, Paris, Munich, and Dubai. Portugal already represents a growing Cloudflare team.
Today, Cloudflare's network currently spans 58 cities in Europe, including Lisbon, Portugal, which was announced in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.cloudflare.com%2Famsterdam-to-zhuzhou-cloudflare-global-network%2F&amp;esheet=54138023&amp;newsitemid=20241018840279&amp;lan=en-US&amp;anchor=2016&amp;index=2&amp;md5=89c437ed99560575fd137ba7cd354fa5">2016</a>. Cloudflare announced its first office in Lisbon in 2019. Since establishing an office in the region, the company has grown from 14 employees to more than 350 in Portugal. Cloudflare plans to significantly increase its presence in Lisbon over the coming years.
Cloudflare celebrated the official opening of its new office with a ribbon cutting ceremony, followed by a reception attended by Portugal's Minister of Economy, Mr. Pedro Reis, along with other Portuguese officials. Top Cloudflare executives were also in attendance, including Cloudflare co-founder and CEO Matthew Prince, and John Graham-Cumming, CTO &amp; Head of the Lisbon office, which he opened in July 2019.

Government

Regulations

Cloudflare Expands European Operations With New Lisbon Headquarters, Plans Major Workforce Growth

Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) will release earnings results for its third quarter, before the<a href="https://www.benzinga.com/quote/SLB/earnings"> opening bell on Friday, Oct. 18.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at 88 cents per share, up from 71 cents per share in the year-ago period. SLB projects to report revenue of $9.25 billion for the quarter, compared to $7.58 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Thursday, SLB agreed to sell its interests in Palliser Block.
SLB shares gained 0.7% to close at $43.99 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580874cb846faa000106ac9d/david-anderson">Barclays analyst David Anderson</a> maintained an Overweight rating and cut the price target from $67 to $63 on Oct. 16. This analyst has an accuracy rate of 63%.</li>
<li>Stifel analyst Stephen Gengaro maintained a Buy rating and cut the price target from $65 to $62 on Oct. 11. This analyst has an accuracy rate of 60%.</li>
<li>BMO Capital analyst Philip Jungwirth maintained an Outperform rating and cut the price target from $60 to $58 on Oct. 10. This analyst has an accuracy rate of 61%.</li>
<li>JP Morgan analyst Arun Jayaram maintained an Overweight and cut the price target from $64 to $60 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Morgan Stanley analyst Connor Lynagh maintained an Overweight rating and slashed the price target from $65 to $60 on Sept. 16. This analyst has an accuracy rate of 60%.</li>
</ul>
Considering buying SLB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="511" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png" alt="" class="wp-image-602108" style="width:705px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-1024x511.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157-768x383.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/18035404/image-157.png 1338w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>

SLB Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled mostly higher on Thursday, with the Dow Jones index climbing to a new record close following the release of economic data.
U.S. initial jobless claims fell by 19,000 in the week ending Oct. 12. U.S. retail sales rose 0.4% month-over-month in September compared to a 0.1% increase in August and higher than market estimates of a 0.3% rise. The Philadelphia Fed Manufacturing Index climbed to 10.3 in October compared to 1.7 in September and topping market estimates of 3.
Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) shares jumped around 9.8% on Thursday following better-than-expected third-quarter earnings and strong fourth-quarter guidance
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and real estate stocks recording the biggest losses on Thursday. However, energy and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 161 points to 43,239.05 on Thursday. The S&amp;P 500 slipped 0.02% to 5,841.47, while the Nasdaq Composite rose 0.04% at 18,373.61 during Thursday's session.
Investors are awaiting earnings results from American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), and Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 71.5, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 69.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

TSMC, Strong Economic Data Push Dow To Fresh Record High: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects American Express Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) to report quarterly earnings at $3.28 per share on revenue of $16.67 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. American Express shares gained 1.8% to $290.91 in after-hours trading.</li>
<li>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion. The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year. Netflix shares climbed 5.1% to $722.35 in the after-hours trading session.</li>
<li>Analysts are expecting The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) to post quarterly earnings at $1.90 per share on revenue of $21.91 billion. The company will release earnings before the markets open. Procter &amp; Gamble shares gained 0.1% to $172.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) posted better-than-expected third-quarter financial results. The company also said it obtained regulatory clearance in South Korea for the da Vinci 5 surgical system in October. Intuitive Surgical shares climbed 6.1% to $502.80 in the after-hours trading session.</li>
<li>Analysts expect Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to report quarterly earnings at 88 cents per share on revenue of $9.25 billion before the opening bell. SLB shares rose 0.4% to $44.16 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41379749/abbvie-is-doing-very-well-but-jim-cramers-favorite-abbott-laboratories">AbbVie Is Doing &#8216;Very Well&#8217; But Jim Cramer&#8217;s Favorite? Abbott Laboratories</a></li>
</ul>
Photo courtesy: Shutterstock

ISRG

NFLX

Netflix, American Express And 3 Stocks To Watch Heading Into Friday

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) founder Michael Saylor encouraged those who doubt the upside potential of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to go short on the company's stock, assuring that it would never sell the cryptocurrency.
What happened: During an interview with journalist Madison Reidy that aired Thursday, Saylor asked skeptics to "love" MicroStrategy if they really "hate" Bitcoin.
"We&#8217;re the perfect instrument to short because I promise you, I won&#8217;t sell it. We&#8217;re going to be leveraged long on Bitcoin," said Saylor, one of the most passionate advocates of the cryptocurrency.
&#8220;I want you to love us if you really hate BTC.&#8221;
Saylor said as a company, MicroStrategy has been consistent and transparent in its policy of buying and holding on to Bitcoin, and it was up to market participants to decide if they wanted to buy, sell, or short their shares.
"When I was a younger man I would have been concerned about people shorting my stock but now I&#8217;m not," Saylor added.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41373332/donald-trump-backed-world-liberty-financial-off-to-a-slow-start-raises-just-4-of-the-token">Donald Trump-Backed World Liberty Financial Off To A Slow Start — Raises Just 4% Of The Token Fundraising Target</a>
Why It Matters: Saylor&#8217;s remarks came amid MicroStratgy&#8217;s audacious Bitcoin gambit, which has transformed the software development firm into a proxy for the world&#8217;s greatest digital asset.
MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40306998/since-embracing-bitcoin-4-years-ago-michael-saylors-microstrategy-has-outperformed-warren-">adopted Bitcoin as its primary reserve asset</a> in 2020, becoming the first publicly listed company to pursue this strategy, and hasn't looked back since then. Today, it holds over $17 billion of its total capital in Bitcoin, <a href="https://bitcointreasuries.net/">according</a> to bitcointreasuries.net.
Saylor projects that by 2045, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40916462/michael-saylor-bitcoin-to-hit-13m-by-2045-will-get-us-to-a-different-place#:~:text=Michael%20Saylor%3A%20Bitcoin%20To%20Hit,To%20A%20Different%20Place'%20%2D%20Benzinga">Bitcoin will constitute 7% of global financial capital</a>, implying a $13 million price per Bitcoin.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Michael Saylor: Why MicroStrategy's Bitcoin funding is NOT a glitch" width="500" height="281" src="https://www.youtube.com/embed/eThjo9wYoF0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Price Action: At the time of writing, Bitcoin was exchanging hands at $67,931.57, up 0.98% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of MicroStrategy closed down 0.35% to $193.42 during Thursday's regular trading session.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41372654/peter-schiff-questions-trump-inspired-bitcoin-pump-one-of-the-promises-he-did-not-make-was">Peter Schiff Question &#8216;Trump-Inspired&#8217; Bitcoin Pump: &#8216;One Of The Promises He Did Not Make Was To Buy Any&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Boss Michael Saylor Taunts Bitcoin Doubters, Challenges Them To Short Company's Stock: 'I Want You To Love Us If You Really Hate BTC'

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Waymo is providing riders who <a href="https://www.benzinga.com/news/24/06/39494723/waymo-autonomous-rides-now-available-to-everyone-in-san-francisco-heres-how-you-can-enjoy-driverless">avail an autonomous ride</a> to select transit stations in San Francisco and the Peninsula $3 credit in a bid to promote public transportation, the company said on Thursday.
What Happened: Waymo will credit $3 to riders&#8217; accounts if they take an autonomous ride to or from eligible Bay Area transit stations. These credits can be used for future rides.
The program started on Oct. 17 and will go on till Nov.15. The credits can be used until Dec. 31, according to a statement from Waymo. 
&#8220;By offering electric rides on demand and improving access to public transit, Waymo One is making daily travel more sustainable and convenient,&#8221; said Adam Lenz, Head of Sustainability and Environment at Waymo.
Why It Matters: Waymo currently operates a fleet of all-electric vehicles that have been customized to enable autonomous driving. The company is delivering over 100,000 paid autonomous rides every week to the public, the company said on Thursday.
Automotive research firm&nbsp;S&amp;P Global Mobility&nbsp;said in September that it deems&nbsp;<a href="https://www.benzinga.com/news/24/09/40792410/us-autonomous-vehicle-sales-to-hit-230k-by-2034-after-progress-resumes-at-alphabets-waymo-gms-cruise" target="_blank" rel="noreferrer noopener">Waymo to be the frontrunner&nbsp;</a>in the field of autonomous vehicles in the U.S.&nbsp;
&nbsp;In July, Alphabet committed&nbsp;to a new multiyear&nbsp;<a href="https://www.benzinga.com/news/24/07/39924838/alphabet-commits-to-another-5b-investment-in-waymo-tesla-ceo-elon-musk-takes-jibe-at-cash-burn-in-un" target="_blank" rel="noreferrer noopener">investment of $5 billion into Waymo</a>&nbsp;to help the company "continue to build the world's leading autonomous driving technology company."
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX&#8217;s Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them:&#8217; Will Offer 10X Increase In Bandwidth And Reduced Latency</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

GOOG

GOOGL

Waymo Offers Free Credits To Riders Traveling To Select Transit Stations In The Bay Area: Here's How Much You Can Get

Coca-Cola Europacific Partners plc (&quot;CCEP&quot; or the &quot;Company&quot;) today confirms notification of transfer of UK listing category from the Equity Shares (Transition) category to the Equity Shares (Commercial Companies) category of the Official List

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-Cola Europacific Partners To Shifts To Commercial Companies Category, Paving The Way For FTSE Index Eligibility

NYCB

Reported Earlier, Flagstar Bank, Subsidiary of New York Community Bancorp, Cuts 8% of Workforce In Strategic Transformation And Cost-Cutting Initiative

Lotus continues to achieve top-rate growth among traditional luxury car brands, delivering 7,543 vehicles1&nbsp;in the first nine months of 2024, representing a year-on-year increase of&nbsp;134%. Global allocation in terms of deliveries remained well-distributed, with Europe, China, North America and the Rest of the World regions each contributing about&nbsp;20-35%&nbsp;of the total deliveries. In the&nbsp;third quarter&nbsp;of 2024, Emeya (GT, Sedan) was delivered to Europe, whilst Eletre (SUV) reached markets including the GCC, Japan and Korea.

Reported Earlier, Lotus Technology Reports 134% YoY Vehicle Delivery Surge In First Nine Months Of 2024

Econ #s

U.K. Retail Sales (YoY) For September 3.9% Vs. 3.2% Est.; 2.3% (Revised) Prior

U.K. Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.0% Prior

U.K. Core Retail Sales (MoM) For September 0.3% Vs. -0.3% Est.; 1.1% Prior

U.K. Core Retail Sales (YoY) For September 4.0% Vs. 3.2% Est.; 2.2% (Revised) Prior

Netflix Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Co-CEO&nbsp;Ted Sarandos on Thursday outlined why the streaming giant continues to hold an edge over YouTube, a subsidiary of Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: During Netflix&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter earnings</a> call, a question about&nbsp;YouTube&#8217;s growing share of TV&nbsp;consumption was raised.
In response, Sarandos highlighted Netflix&#8217;s commitment to investing in premium content to increase viewer engagement, stating, &#8220;Netflix is the best place&nbsp;for premium stories because we&#8217;re&nbsp;the home to the best&nbsp;storytellers.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
Regarding YouTube, he said, &#8220;When I look at YouTube specifically, I&#8217;d say look, we compete directly with YouTube for people&#8217;s time, for the time they spend on that TV screen. But we have very different strengths.&#8221;
Another, Netflix Co-CEO Greg Peters added that Netflix plays a crucial role for consumers seeking high-quality movies and TV shows, and for creators looking for partners willing to share the inherent risks of bringing stories to life.
&#8220;A Hundred Years of Solitude, Senna, both coming from Latin America, which are huge, ambitious projects. It&#8217;s hard to imagine how those kind of big creative bets would be possible with YouTube&#8217;s model,&#8221; Peters stated.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Netflix&#8217;s third-quarter financial results showed a 15% year-over-year increase in revenue, beating Street consensus estimates.
Moreover, Netflix&#8217;s recent foray into live sports programming indicates a strategic shift from its traditional on-demand model. This move aims to capture high-impact moments and the <a href="https://www.benzinga.com/general/entertainment/24/10/41395213/netflixs-200b-hour-problem-why-live-sports-are-just-a-drop-in-the-streaming-ocean">excitement of global live events</a>, further enhancing viewer engagement.
During the <a href="https://www.benzinga.com/news/earnings/24/07/39849026/netflix-q2-earnings-highlights-revenue-beat-eps-beat-advertising-revenue-more-meaningful-squid-game" target="_blank" rel="noreferrer noopener">second-quarter earnings</a> call, Netflix executives were asked questions about YouTube.
At the time, Sarandos&nbsp;said, &#8220;So our two services — us and YouTube represent about 50% of all streaming to the TV in the U.S. and we use the U.S. only because that's where we have the data.&#8221;
&#8220;So really what we're focused on here is focusing ourselves on that other 80% of total TV time that isn't going to either us or YouTube,&#8221; he said in July.
Sarandos <a href="https://www.benzinga.com/general/entertainment/24/07/39853498/netflix-aims-to-capture-broader-tv-market-sees-youtube-as-both-competitor-and-partner-we-ki">reiterated Netflix&#8217;s commitment to focus</a> on the remaining 80% of the market during the third-quarter call too.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41356479/apple-spark-hope-for-americas-semiconductor-comeback-key-supplier-tsmc-reportedly-begins-producing-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Spark Hope For America&#8217;s Semiconductor Comeback: Key Supplier TSMC Reportedly Begins Producing Chips In US For iPhone Maker</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Entertainment

Equities

Netflix's Ted Sarandos Downplays Concerns Of YouTube's Growing Share Of TV Consumption: 'We're The Home To The Best Storytellers'

Orders and deliveries
In Q3, net order intake decreased by 8% to 43,234 trucks and deliveries decreased by 16% to 46,266 units. Deliveries of heavyduty trucks decreased by 9%, of medium-duty trucks by 21% and of light-duty trucks by 61%.

VLVLY

Volvo's Q3 Saw 8% Drop In Net Order Intake To 43,234 Trucks, With Deliveries Down 16% To 46,266 Units

Volvo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLVLY#OTC">VLVLY</a>) reported quarterly earnings of $0.47 per share. This is a 26.18 percent decrease over earnings of $0.64 per share from the same period last year. The company reported $11.22 billion in sales this quarter. This is a 8.38 percent decrease over sales of $12.25 billion the same period last year

VLVCY

Volvo Q3 EPS $0.47 Down From $0.64 YoY, Sales $11.22B Down From $12.25B YoY

Candel Therapeutics GAAP EPS of -$0.28

SCWorx, Cue Health, Sensei Biotherapeutics among healthcare movers

Candel gains FDA orphan status for brain tumor candidate

Candel Therapeutics to join Russell 3000 Index

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Let me be clear: investing in <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> isn&rsquo;t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers high return potential if they make significant advancements in health care.



Biotech stocks represent companies that are involved in the research and development of drugs, therapies and medical devices. They include companies that work in fields such as genomics, biopharmaceuticals, bioinformatics and medical diagnostics.



A-rated biotech stocks are highly coveted because they are at the forefront &mdash; or in the midst of &mdash; groundbreaking innovation. 



A biotech company that wins regulatory approval for a new drug can see a huge increase in stock price, providing lucrative returns to investors and billions of dollars in annual profit for the company.



But remember &mdash; bringing a drug to market costs a lot of money. Biotech stocks must absorb high research and development costs through laboratory research, preclinical trials and multiple phases of clinical trials. 



It can take years to bring a drug to market, or even to get it in front of the Food and Drug Administration for approval. Any setback can derail the drug pipeline and cause the stock price to collapse.



By using the Portfolio Grader, we can identify A-rated biotech stocks based on analyst sentiment, earnings performance, growth and stock buying momentum. If you want to try your hand in the biotech sector, these A-rated biotech stocks are a good place to start.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>) can arguably be considered the best biotech stock on the market right now. 



The Indianapolis-based biotech company is set to make billions of dollars a year through its weight-loss treatment drug. And now there&rsquo;s yet another catalyst that is sending LLY stock higher.



First, let&rsquo;s talk about Zepbound, which is Lilly&rsquo;s FDA-approved drug to help people lose weight. The injectable drug won FDA approval in November 2023, so Lilly is just getting started on a long run of profits. About 42% of the U.S. population is obese and the window for Lilly to profit from Zepbound is huge.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes.



The drugs are so popular that Lilly is&nbsp;<a href="https://investor.lilly.com/news-releases/news-release-details/lilly-increases-manufacturing-investment-9-billion-newest">increasing its investment</a>&nbsp;in its Indiana manufacturing facility from $3.7 billion to $9 billion to increase the production of tirzepatide and other pipeline products.



And now Lilly is set to score big on another treatment. An FDA panel voted unanimously in favor of the company&rsquo;s <a href="https://investorplace.com/2024/06/eli-lilly-stock-hits-new-52-week-high-as-fda-panel-recommends-alzheimers-drug/">donanemab&nbsp;</a>drug, which would be used to treat Alzheimer&rsquo;s. The full FDA still needs to give final approval, but the unanimous recommendation of its panel is a very good sign.



LLY stock reached a new 52-week high on the news. The stock is now up 48% on the year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/biotech-stocks-2-300x169.jpg" alt="A close-up concept image of a tiny glass vial with a strand of DNA in it. best biotech stocks"><div>Source: Shutterstock</div></div>Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is a much different biotech company than Lilly. But the company has its own wins and is worthy of its status as an A-rated biotech stock.



Lexaria developed DehydraTECH, which is a drug delivery technology that improves the way active pharmaceutical ingredients enter the bloodstream.



Lexaria says its platform promotes healthier delivery methods and increases the effectiveness of drugs that are delivered by tablets, capsules and oral suspensions.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field. 



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



While R&amp;D costs are still outweighing profits, there&rsquo;s good reason to be bullish on LEXX stock, which is already up 159% this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) has some of the same catalysts are work that are pushing LLY stock higher. 



The European company has an injectable weight loss drug of its own, called Wegovy. Wegovy was approved in 2021 by U.S. regulators to treat weight loss and recently as also approved for treatment in the U.K.



Wegovy&rsquo;s popularity has led to shortages in some pharmacies as Novo Nordisk struggles to keep up with demand. The company&rsquo;s running its manufacturing operations 24 hours a day to meet demand.



Novo Nordisk has another huge drug on the market, Ozempic, which is a treatment for type 2 diabetes.



<a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=168508">Earnings for the first quarter</a> included days of 65.3 billion Danish kroner ($9.46 billion), up 22% from a year ago. Operating profit was up 27%, and net profits were up 29%.



Novo Nordisk reported earnings per share of 5.68 Danish kroner (85 cents per share), which was up 29% from a year ago.



NVO stock is up 38% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/ocgn1600-2-300x169.png" alt="Person holding cellphone with webpage of US biopharmaceutical company Ocugen Inc (OCGN) on screen in front of logo Focus on center of phone display"><div>Source: Wirestock Creators / Shutterstock.com</div></div>Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is a small biotech company based in Pennsylvania. With a market capitalization of less than $400 million, Ocugen is working on developing and commercializing gene and cell therapies.



The company has a breakthrough modifier gene therapy platform that has the potential to treat multiple retinal disease with a single product, which could be highly lucrative if brought to market.



The company has <a href="https://ocugen.com/therapeutic-areas/">multiple retinal products</a> in various phases of testing in an effort to treat hard-to-treat eye disease. 



It also has a treatment in Phase 3 testing to treat knee cartilage damage and ideally help prevent osteoarthritis, and it has started on a potential inhaled vaccine that would help prevent Covid-19.



The company&rsquo;s stock will get a boost later this month when it joins the Russell 3000, an inclusion that should improve the trading volume as funds that track the index purchase OCGN shares.



The company reported <a href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2024-financial">cash and cash equivalents</a> of $25.4 million at the end of the first quarter, with total operating expenses for the quarter of $13.2 million. 



Bringing a drug to market is expensive. But since it has FDA approval for Phase 3 trials for its retinal treatment, the company is on the verge of bringing to market a treatment that affects an estimated 300,000 people in the U.S. and Europe.



OCGN stock still trades for less than $2 per share, but probably won&rsquo;t be that low for long. The stock is up 154% so far in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Candel Therapeutics (CADL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/biotech_bigpharma1600-300x169.png" alt="Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock"><div>Source: Hernan E. Schmidt / Shutterstock.com</div></div>Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) is a Massachusetts that works with viral immunotherapies in an effort to treat cancer. 



Its treatment platform includes combining an anti-tumor component and an immune-stimulatory component to attack malignant cells.



The company developed two clinical stage investigational viral immunotherapies designed to produce an individualized cancer response, based on genetically modified adenovirus and herpes simplex virus gene constructs, respectively.



It currently has several drug candidates in Phase 2 and Phase 3 trials, including treatments for prostate, lung and pancreatic cancer. Like Ocugen, Candel is also joining the Russell 3000 this year.



The company had <a href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2024-financial-results">cash and cash equivalents</a> of $25.7 million at the end of the first quarter, which is says will be sufficient to fund operations into the fourth quarter. R&amp;D expenses in the first quarter were only $4.1 million, while general and administrative expenses were only $3.8 million.



CADL stock soared since April and is now up more than 400% this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Teva Pharmaceutical (TEVA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/teva1600a-300x169.jpg" alt="Opioids Made TEVA Stock Untouchable But Things Seem to be Changing"><div>Source: JHVEPhoto / Shutterstock.com</div></div>Teva Pharmaceutical (NYSE:<a href="https://investorplace.com/stock-quotes/teva-stock-quote/">TEVA</a>) is a leading manufacturer of generic pharmaceuticals. Once a company loses exclusivity in a drug several years after bringing it to market, any drug manufacturer can offer a generic equivalent that can be sold for less than the name-brand drug. That&rsquo;s where Teva comes in.



Teva says nearly 200 million people around the world use drugs that it manufacturers, with production sites in 53 locations spanning 33 countries. The company says its generic equivalents help patients save more than $40 billion a year in health care costs.



One of its <a href="https://investorplace.com/2024/02/teva-stock-pops-4-as-teva-receives-fda-approval/">newest treatments</a> is with a strategic partner, Alvotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/alvo-stock-quote/">ALVO</a>), which won FDA approval for an injectable drug to be used as an alternative to Humira, which is a prescription drug to treat rheumatoid arthritis. 



Humira is made by AbbVie (NYSE:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>), and was one of the biggest pharmaceutical products in the world last year with $12.2 billion in sales.



Revenue for the first quarter was $1.72 billion, up from $1.67 billion a year ago. The company reported profits of $350 million, up from $338 million in the first quarter of 2023.



TEVA stock is up 64% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>GSK (GSK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/gsk-stock-1-300x169.jpg" alt="A GlaxoSmithKline (GSK) office in London."><div>Source: Willy Barton / Shutterstock.com</div></div>GSK (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>), also known as GlaxoSmithKline, is a British biotech company that focuses on making treatments for infectious diseases, HIV, immunology and respiratory conditions and cancer.



Its top drugs include Calpol, which treats cold systems in infants; Ceftum, an antibiotic, and Neosporin, which in cream form treats skin pain, itches and wounds.



The company has more than 70 vaccine candidates and specialty medications in clinical development, with 18 in Phase 3 testing.



Sales in the first quarter were 7.4 billion British pounds ($9.46 billion), up 10% from a year ago. Profits were 2.4 billion British pounds, up 27% from a year ago.



GSK stock is up 11% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier had long positions in NVO and LLY. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-biotech-stocks-worth-betting-on-in-june/">7 A-Rated Biotech Stocks Worth Betting on in June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Biotech Stocks Worth Betting on in June

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

3 Biotech Names With Potential Catalysts By Year End

Candel Therapeutics GAAP EPS of -$0.74

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Candel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cadl-stock-quote/">CADL</a>) just reported results for the second quarter of 2024.<ul><li>Candel Therapeutics reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cadl-stock-earnings-candel-therapeutics-for-q2-of-2024/">CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024

Buy Stocks Now, Here Are 3 Categories

ABBV

AFRM

AKAN

AMGN

BHVN

BIIB

BSQKZ

CADL

FNCH

GNLX

GTLB

HLTH

IOVA

LEXX

NVDA

OCGN

ONMD

PLTR

PYPL

RCKT

SARO

SNOW

SNSE

TEVA

TGTX

VKTX

VRDN

WORX

Screenshot 2024-06-13 at 5.29.56 PM

Biotech

Candel Therapeutics&#39; (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Screenshot 2024-06-06 at 5.30.54 PM

Candel Therapeutics&#39; (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Screenshot 2024-05-31 at 5.22.29 PM

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Screenshot 2024-04-04 at 9.54.11 PM

Chief Science Officer Talks Innovation In Cancer Research

Screenshot 2024-03-25 at 6.13.53 PM

The CEO Of This Innovative BioPharma Is Bringing Light To Cancer Research

Screenshot 2024-03-14 at 5.26.26 PM

Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors

Screenshot 2024-03-05 at 6.31.45 PM

CGON

CLDI

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-27 at 6.29.08 PM

Moving Fast: Candel&#39;s (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer

Health Care

Press Releases

Candel Therapeutics to Join Russell 3000® Index

Opinion

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Small Cap

Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Management

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Comments

Candel Therapeutics

Notizie

Ultime notizie per Candel Therapeutics (NASDAQ:CADL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO